Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

1 Jan 2022

Abstract excerpt

Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare system. Methods: A cost-effectiveness analysis was conducted using a decision analytic Markov model from the Canadian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35923926
DOI: 10.1177/17588359221112696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancerPMID 35923926Read ↗

Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) PatientsSemantic proximity Read ↗

Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.Semantic proximity Read ↗

Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.Semantic proximity Read ↗

Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.Semantic proximity Read ↗

Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancerSemantic proximity Read ↗

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancerSemantic proximity Read ↗

Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.Semantic proximity Read ↗

Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients.Semantic proximity Read ↗

Costs of Next-Generation Sequencing Assays in Non-Small Cell Lung Cancer: A Micro-Costing StudySemantic proximity Read ↗

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS EraSemantic proximity Read ↗

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.